2014 Q4 Form 10-Q Financial Statement
#000156459014005463 Filed on November 12, 2014
Income Statement
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
Revenue | $0.00 | $0.00 | |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $5.550M | $1.710M | |
YoY Change | |||
% of Gross Profit | |||
Research & Development | $5.050M | $2.000M | $1.134M |
YoY Change | 76.37% | ||
% of Gross Profit | |||
Depreciation & Amortization | $10.00K | $0.00 | |
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $10.60M | $5.949M | $2.552M |
YoY Change | 133.11% | ||
Operating Profit | -$5.949M | -$2.552M | |
YoY Change | 133.11% | ||
Interest Expense | $70.00K | $30.00K | |
YoY Change | |||
% of Operating Profit | |||
Other Income/Expense, Net | |||
YoY Change | |||
Pretax Income | -$10.53M | -$5.919M | -$2.549M |
YoY Change | 132.21% | ||
Income Tax | $0.00 | $0.00 | -$13.00K |
% Of Pretax Income | |||
Net Earnings | -$10.53M | -$5.919M | -$2.536M |
YoY Change | 133.4% | ||
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$2.110M | -$292.9K | |
COMMON SHARES | |||
Basic Shares Outstanding | 20.21M | ||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $104.1M | $51.70M | |
YoY Change | |||
Cash & Equivalents | $21.90M | $25.70M | $15.69M |
Short-Term Investments | $82.20M | $26.00M | |
Other Short-Term Assets | $1.900M | $300.0K | |
YoY Change | |||
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $106.0M | $52.02M | |
YoY Change | 104.65% | ||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $48.00K | $14.00K | |
YoY Change | 500.0% | ||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $48.00K | $2.084M | |
YoY Change | 300.0% | ||
Total Long-Term Assets | $96.00K | $2.098M | |
YoY Change | 380.0% | ||
TOTAL ASSETS | |||
Total Short-Term Assets | $106.0M | $52.02M | |
Total Long-Term Assets | $96.00K | $2.098M | |
Total Assets | $106.1M | $54.12M | |
YoY Change | 104.76% | ||
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $440.0K | $569.0K | |
YoY Change | -27.39% | ||
Accrued Expenses | $1.200M | $500.0K | |
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.724M | $2.412M | |
YoY Change | 78.74% | ||
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Other Long-Term Liabilities | $216.0K | $165.0K | |
YoY Change | -6.09% | ||
Total Long-Term Liabilities | $216.0K | $165.0K | |
YoY Change | -6.09% | ||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.724M | $2.412M | |
Total Long-Term Liabilities | $216.0K | $165.0K | |
Total Liabilities | $2.940M | $2.577M | |
YoY Change | 67.62% | ||
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$40.89M | -$30.36M | |
YoY Change | 217.39% | ||
Common Stock | $144.2M | ||
YoY Change | 6450.25% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $103.2M | -$23.03M | |
YoY Change | |||
Total Liabilities & Shareholders Equity | $106.1M | $54.12M | |
YoY Change | 104.76% |
Cashflow Statement
Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$10.53M | -$5.919M | -$2.536M |
YoY Change | 133.4% | ||
Depreciation, Depletion And Amortization | $10.00K | $0.00 | |
YoY Change | |||
Cash From Operating Activities | -$4.960M | -$4.090M | |
YoY Change | 18.66% | ||
INVESTING ACTIVITIES | |||
Capital Expenditures | -$40.00K | $0.00 | |
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$56.90M | -$1.430M | |
YoY Change | |||
Cash From Investing Activities | -$56.93M | -$1.440M | |
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 58.08M | -550.0K | |
YoY Change | 51.17% | ||
NET CHANGE | |||
Cash From Operating Activities | -4.960M | -4.090M | |
Cash From Investing Activities | -56.93M | -1.440M | |
Cash From Financing Activities | 58.08M | -550.0K | |
Net Change In Cash | -3.810M | -6.080M | |
YoY Change | -111.13% | ||
FREE CASH FLOW | |||
Cash From Operating Activities | -$4.960M | -$4.090M | |
Capital Expenditures | -$40.00K | $0.00 | |
Free Cash Flow | -$4.920M | -$4.090M | |
YoY Change | 17.7% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001604464 | ||
CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
12000 | |
CY2013Q4 | us-gaap |
Assets
Assets
|
51828000 | |
CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
606000 | |
CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
432000 | |
CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1524000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
25996000 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
193000 | |
CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8000 | |
CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
1754000 | |
CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
51808000 | |
CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2013Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
230000 | |
CY2013Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
331000 | |
CY2013Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
155000 | |
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
CY2014Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
20212889 | |
CY2014Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25703000 | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
51615000 | |
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
CY2014Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
4241000 | |
CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1708000 | |
CY2013Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
868000 | |
CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
5949000 | |
CY2013Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
2552000 | |
CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5949000 | |
CY2013Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2552000 | |
CY2014Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5919000 | |
CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2549000 | |
CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5919000 | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4328000 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Atara Biotherapeutics, Inc. | ||
CY2013Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
977778 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1337501 | ||
CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2536000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-17479000 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
910839 | ||
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-11017000 | |
CY2014Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
54120000 | |
CY2014Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-11000 | |
CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
51828000 | |
CY2014Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-30362000 | |
CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-12883000 | |
CY2014Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-23029000 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12951191 | ||
CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1410507 | |
us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-13.07 | ||
us-gaap |
Depreciation
Depreciation
|
4000 | ||
CY2014Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-11000 | |
CY2014Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-4.20 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1017000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1017000 | ||
us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
2000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
34000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-33000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-37000 | ||
CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
2200000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-3000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-11671000 | ||
us-gaap |
Interest Income Other
InterestIncomeOther
|
8000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-17501000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5190000 | ||
CY2013Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-13000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-22000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
27000 | ||
CY2014Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
323000 | |
CY2014Q3 | us-gaap |
Assets Current
AssetsCurrent
|
52022000 | |
CY2014Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14000 | |
CY2014Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2084000 | |
CY2014Q3 | us-gaap |
Assets
Assets
|
54120000 | |
CY2014Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
569000 | |
CY2014Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
500000 | |
CY2014Q3 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
63000 | |
CY2014Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1280000 | |
CY2014Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2412000 | |
CY2014Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
165000 | |
CY2014Q3 | us-gaap |
Liabilities
Liabilities
|
2577000 | |
CY2014Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2014Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
7344000 | |
CY2013Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
2200000 | |
CY2013Q4 | atra |
Notes Receivable From Stockholders Equity
NotesReceivableFromStockholdersEquity
|
-335000 | |
CY2014Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2014Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1509712 | |
CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
12003891 | |
CY2014Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1509712 | |
CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
12003891 | |
CY2013Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
1134000 | |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
9332000 | ||
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
2057000 | ||
CY2013Q3 | atra |
Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
|
550000 | |
atra |
Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
|
1066000 | ||
atra |
Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
|
550000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7162000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2591000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
17560000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
5198000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17560000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5198000 | ||
CY2014Q3 | us-gaap |
Interest Income Other
InterestIncomeOther
|
30000 | |
CY2013Q3 | us-gaap |
Interest Income Other
InterestIncomeOther
|
3000 | |
us-gaap |
Interest Income Other
InterestIncomeOther
|
59000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-5217000 | ||
CY2014Q3 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-11000 | |
us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-11000 | ||
us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-11000 | ||
CY2014Q3 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-5930000 | |
CY2013Q3 | us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-2536000 | |
us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-17490000 | ||
us-gaap |
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
-5217000 | ||
CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-2.59 | |
us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-5.73 | ||
us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
750000 | ||
us-gaap |
Depreciation
Depreciation
|
3000 | ||
atra |
Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
|
251000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
28618000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
10000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-26428000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
14963000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
11483000 | ||
CY2013Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15690000 | |
us-gaap |
Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
|
249000 | ||
us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
3000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
5000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
523000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
512000 | ||
us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
-92000 | ||
us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
11000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
440000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
542000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
169000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
186000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-3477000 | ||
us-gaap |
Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
|
337000 | ||
us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
13500000 | ||
us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
15087000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
12187000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-25912000 | ||
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4207000 | |
us-gaap |
Stock Issued1
StockIssued1
|
750000 | ||
atra |
Issuance Of Convertible Preferred Stock In Exchange For License
IssuanceOfConvertiblePreferredStockInExchangeForLicense
|
1003000 | ||
atra |
Change In Obligation To Issue Convertible Preferred Stock
ChangeInObligationToIssueConvertiblePreferredStock
|
-1003000 | ||
atra |
Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
|
65000 | ||
atra |
Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
|
80000 | ||
atra |
Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
|
-65000 | ||
atra |
Restricted Stock Issued To Related Party In Exchange For Notes Receivable
RestrictedStockIssuedToRelatedPartyInExchangeForNotesReceivable
|
331000 | ||
atra |
Offering Costs In Anticipation Of Initial Public Filing Included In Accrued Liabilities And Accounts Payable
OfferingCostsInAnticipationOfInitialPublicFilingIncludedInAccruedLiabilitiesAndAccountsPayable
|
407000 | ||
us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
13000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
209959 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these combined and consolidated financial statements include the fair value of common stock, the fair value of preferred stock and estimates related to clinical trial accruals. Actual results could differ materially from those estimates. </p></div> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also have short-term investments in money market funds, corporate bonds and commercial paper backed by US Government or private insurers, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. </p></div> | ||
CY2014Q3 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
26007000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
14000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
25996000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
24917000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
1090000 | |
dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Delaware | ||
dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2012-08-01 | ||
CY2014Q3 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.7692 | |
atra |
Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
|
P90D | ||
atra |
Investment Maturity Period
InvestmentMaturityPeriod
|
P90D | ||
CY2014Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
26007000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
24906000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
1090000 | |
CY2014Q3 | us-gaap |
Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
|
25996000 | |
us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | ||
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | ||
atra |
Expense Recognized On Employee Awards Subject To Service And Performance Conditions
ExpenseRecognizedOnEmployeeAwardsSubjectToServiceAndPerformanceConditions
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | ||
CY2014Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12930215 | |
CY2013Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6594208 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5983828 | ||
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
209959 | |
CY2012Q3 | us-gaap |
License Costs
LicenseCosts
|
250000 | |
CY2014Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
31900 | |
us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2014-10-31 | ||
CY2014Q3 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
12298515 | |
CY2014Q3 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
12298515 | |
CY2014Q3 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
74572000 | |
CY2013Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
95423541 | |
CY2013Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
61091000 | |
CY2013Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
95423541 | |
CY2013Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
102774840 | |
us-gaap |
Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
|
The stockholders of Nina, Pinta and Santa Maria exchanged three shares of each company’s preferred stock for one share of Atara preferred stock (a collective nine-for-one basis). | ||
us-gaap |
Convertible Preferred Stock Settlement Terms
ConvertiblePreferredStockSettlementTerms
|
Each share of convertible preferred stock, subject to certain anti-dilution adjustments, will be automatically converted into one fully paid and nonassessable share of common stock at the applicable conversion rate upon the earlier of: (i) an initial public offering with a pre-initial public offering valuation that results in a price to the public of at least three times the Series B issue price (reduced to 1.6 times following the Recapitalization—see Note 2) | ||
CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
162461535 | |
atra |
Cancellation Of Shares Authorized Increase Decrease For Period
CancellationOfSharesAuthorizedIncreaseDecreaseForPeriod
|
923076 | ||
atra |
Tender Of Shares Authorized Increase Decrease For Period
TenderOfSharesAuthorizedIncreaseDecreaseForPeriod
|
161538459 | ||
atra |
Stock Authorized During Period Shares Period Increase Decrease
StockAuthorizedDuringPeriodSharesPeriodIncreaseDecrease
|
17948717 | ||
CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
17948717 | |
us-gaap |
Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
|
644710 | ||
atra |
Cancellation Of Outstanding Shares Increase Decrease For Period
CancellationOfOutstandingSharesIncreaseDecreaseForPeriod
|
923076 | ||
atra |
Tender Of Shares Outstanding Increase Decrease For Period
TenderOfSharesOutstandingIncreaseDecreaseForPeriod
|
11725525 | ||
us-gaap |
Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
|
1302835 | ||
us-gaap |
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
|
147116 | ||
us-gaap |
Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
|
59761 | ||
CY2013Q4 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
2201000 | |
CY2013Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
15133178 | |
CY2014Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
432000 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
4261774 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
144951 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
9492565 | |
CY2014Q1 | atra |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Recapitalization Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRecapitalizationShares
|
8437856 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1054709 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
36058 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
66153 | ||
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
966190 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
0.133 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
0.045 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
0.402 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
3.619 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
0.404 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
8.593 | ||
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
3.561 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
0 | |
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
0 | ||
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
209959 | |
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
0 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0 | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
12.55 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | ||
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.55 | |
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
12.55 | |
CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M17D | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y10M17D |